Viewing nowCombinationExmetrex XR Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Sciences Co., Ltd.

MFDS item code 202202075 · Approved 2022.05.17 · Insurance code 671707150
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used as an adjunct to help control blood sugar in patients with type 2 diabetes when used in conjunction with dietary and exercise therapies, contributing to the effective management of blood sugar levels. It helps to stabilize the patient's blood glucose levels.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, with gradual dose escalation. To maintain its extended-release properties, swallow this medication whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior history of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication. 2. Patients being treated with metformin: The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at their current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg. The initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be gradually increased to reduce gastrointestinal adverse reactions caused by metformin. When this medication is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin.
This medication consists of sitagliptin and metformin and is used for diabetes treatment. First, sitagliptin can rarely cause severe allergic reactions, so if symptoms like hives, rash, or difficulty breathing occur, discontinue use immediately and consult a physician. Additionally, sitagliptin may lead to a serious side effect called pancreatitis, which involves inflammation of the pancreas; if symptoms like abdominal pain, vomiting, or nausea persist, notify healthcare professionals immediately. The metformin ingredient can cause lactic acidosis, a rare but potentially fatal metabolic disorder; if sudden muscle pain, difficulty breathing, fatigue, abdominal pain, or weakness occurs, stop taking the medication immediately and visit a hospital. This medication should not be administered to patients with impaired kidney function, severe infections, dehydration, heart failure, or acute myocardial infarction, and it should be suspended for a certain period before and after imaging tests using iodinated contrast agents. It is advisable for pregnant or nursing women and children under 18 years of age not to use this medication. While taking this medication, regular checks of kidney function, blood tests, and vitamin B12 levels are necessary, and excessive alcohol consumption should be avoided. Also, irregular meals, excessive exercise, or combining with other hypoglycemic agents can increase the risk of hypoglycemia, so caution is required. If surgery is planned, medication should be stopped 48 hours prior to the procedure and resumed only after normal kidney function is confirmed post-surgery. During the course of taking this medication, gastrointestinal disorders, headaches, and upper respiratory infections may occur; if symptoms are severe, consult a physician. Finally, while this medication assists with blood sugar control, it is essential to adhere to dietary and exercise protocols, along with regularly monitoring blood sugar and kidney function for safe treatment.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture ingress, ideally at room temperature between 1°C and 30°C. By doing so, the effectiveness of the medication can be maintained for a longer period.
Bright green, oval-shaped, biconvex, sustained-release film-coated tablet
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Sciences Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.